Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;26(6):459-468.
doi: 10.1007/s11916-022-01046-6. Epub 2022 Apr 23.

Patients on Buprenorphine Formulations Undergoing Surgery

Affiliations
Review

Patients on Buprenorphine Formulations Undergoing Surgery

Katelynn Champagne et al. Curr Pain Headache Rep. 2022 Jun.

Abstract

Purpose of review: To review the pharmacology of buprenorphine, the evolution of buprenorphine dosing recommendations, and the current literature regarding its recommendations for the perioperative period.

Recent findings: There is a consensus that for all surgeries, buprenorphine should be continued throughout the perioperative period. If the surgery is a minimal to mild pain surgery, no dose adjustment is needed. There is no clear consensus regarding moderate to severe pain. With all surgeries, multimodal analgesia should be utilized, with regional anesthesia when possible. Patients taking buprenorphine should continue their buprenorphine perioperatively; whether to decrease or maintain dosing is up for debate. Multimodal analgesia should also be used throughout the perioperative period, and communication between the patient and all provider teams is of the utmost importance to provide adequate analgesia during the perioperative period, as well as to arrange safe analgesia upon discharge.

Keywords: Buprenorphine; Buprenorphine pharmacology; Multimodal analgesia; Perioperative buprenorphine; Pre-operative buprenorphine, Post-operative buprenorphine.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Campbell ND, Lovell AM. The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci. 2012;1248:124–39. https://doi.org/10.1111/j.1749-6632.2011.06352.x .
    1. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis. 2006;43(Suppl 4):S197-215. https://doi.org/10.1086/508184 . - DOI - PubMed
    1. Kohan L, Potru S, Barreveld AM, Sprintz M, Lane O, Aryal A, Emerick T, Dopp A, Chhay S, Viscusi E. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med. 2021;46(10):840–59. https://doi.org/10.1136/rapm-2021-103007 . - DOI - PubMed
    1. Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther. 2020;9(1):41–54. https://doi.org/10.1007/s40122-019-00143-6 . - DOI - PubMed - PMC
    1. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–80. https://doi.org/10.1038/clpt.1994.71 . - DOI - PubMed

LinkOut - more resources